Advent Technologies (ADN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for October 22, 2025, and will be held virtually, allowing shareholders to vote and submit questions online.
Shareholders of record as of September 19, 2025, are entitled to vote on all proposals, with 3,291,634 shares outstanding as of the record date.
The board recommends voting in favor of all proposals, including director elections, auditor ratification, stock issuance, incentive plan amendment, executive compensation, and meeting adjournment if necessary.
Forward-looking statements are included, highlighting risks and uncertainties regarding future performance and plans.
Voting matters and shareholder proposals
Seven proposals are up for vote: election of three Class II directors, ratification of M&K CPAS as auditor, approval of potential issuance of 20%+ of common stock to Hudson Global, amendment to the 2021 Incentive Plan, advisory vote on executive compensation, advisory vote on frequency of say-on-pay, and transaction of other business.
The board recommends a three-year frequency for future say-on-pay votes.
Shareholders can vote by internet, phone, mail, or during the virtual meeting.
Board of directors and corporate governance
The board consists of six members divided into three classes with staggered terms; four are independent under Nasdaq rules.
Board committees include audit, compensation, and nominating/governance, each with defined responsibilities and independent members.
The board has adopted corporate governance guidelines and a code of business conduct and ethics, available on the company website.
Directors are encouraged to attend the annual meeting, and shareholders can communicate directly with the board.
Latest events from Advent Technologies
- Q4 revenue and cash fell as cost cuts and partnerships drove a shift to licensing and MEA focus.ADN
Q4 202323 Jan 2026 - Director and auditor ratified; other business matters not approved at the meeting.ADN
AGM 202410 Jan 2026 - Annual meeting to elect a director, ratify auditor, and address other business, all board-recommended.ADN
Proxy Filing1 Dec 2025 - Seeks up to $52M equity funding amid losses and going concern risk, leveraging HT-PEM tech and partnerships.ADN
Registration Filing28 Nov 2025 - Liquidity crisis persists despite improved net income; delisted, high debt, and major legal risks remain.ADN
Q3 202517 Nov 2025 - All agenda items, including director elections and plan amendments, were approved by majority vote.ADN
AGM 202522 Oct 2025 - Severe liquidity challenges, legal settlements, and a major EU grant defined the quarter.ADN
Q2 202512 Aug 2025 - Severe liquidity challenges persist despite cost cuts and a major EU grant, with going concern risks looming.ADN
Q1 202530 Jun 2025 - Revenue up 113% year-over-year, but severe liquidity risk and going concern doubts persist.ADN
Q4 202530 Jun 2025